Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxegol for Opioid-Related Gastroparesis
NCT03036891Phase 2Withdrawn
- Sponsor
- Temple University
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naloxegol in gastroparesis (2 arms), sponsored by Temple University. Primary endpoint: Gastric Emptying Half-Time at 4 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
naloxegol
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT03036891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036891.